Pfizer

PFE

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$47.3m

Combined value at quarter end

Last quarter

3 bought

3 sold or trimmed

Price at Q2 ’26 end

$24.08

-14.2% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+3.4%Q3 ’24

-8.3%Q4 ’24

-4.5%Q1 ’25

-4.3%Q2 ’25

+5.1%Q3 ’25

-2.3%Q4 ’25

+12.8%Q1 ’26

-14.2%Q2 ’26

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

7Q4 ’23

6Q1 ’24

6Q2 ’24

6Q3 ’24

6Q4 ’24

6Q1 ’25

5Q2 ’25

5Q3 ’25

5Q4 ’25

5Q1 ’26

6Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Pfizer.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Pfizer

Kahn Brothers	1.8%$11.2m	$11.2m	Trimmed -4.3%	53 qtrs
Fairfax Financial Holdings	0.9%$25.1m	$25.1m	Added +5.3%	23 qtrs
Fairholme Capital Management	0.4%$5.6m	$5.6m	New	1 qtr
Horizon Kinetics	0.0%$1.7m	$1.7m	Added +1.0%	30 qtrs
Mairs & Power	0.0%$1.6m	$1.6m	Trimmed -5.8%	53 qtrs
Dodge & Cox	0.0%$2.1m	$2.1m	Trimmed -0.8%	53 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works

From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.

Sort by

Insider purchases and sales of Pfizer
		Bought or sold				Filing
12 Aug 2026	Bourla AlbertChairman & CEO	▲ Bought	38,000	$26.34	$1.0m	Form 4
5 Aug 2026	Blaylock Ronald EDirector	▲ Bought	39,231	$25.46	$999k	Form 4
5 Aug 2026	Buckley Mortimer JDirector	▲ Bought	37,632	$25.52	$960k	Form 4
5 Aug 2026	Damico Jennifer B.SVP & Controller	▼ Sold	3,278	$25.40	$83k	Form 4

About the company

Sector: Health care · Pharmaceutical Preparations
Incorporated in: Delaware
Financial year ends: 31 December
Shares outstanding: 5.70bn at 29 Jul 2026
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

$52bn2013

2015

$53bn2017

$41bn2019

$81bn2021

$60bn2023

$63bn2025

Pfizer revenue and net income by year
Year	Revenue	Net income
2025	$63bn	$7.8bn
2024	$64bn	$8.0bn
2023	$60bn	$2.1bn
2022	$101bn	$31bn
2021	$81bn	$22bn
2020	$42bn	$9.2bn
2019	$41bn	$16bn
2018	$41bn	$11bn
2017	$53bn	$21bn
2016	$53bn	$7.2bn
2015	–	$7.0bn
2014	–	$9.1bn
2013	$52bn	$22bn

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.